Neurobo Pharmaceuticals Inc

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. Show More...

  • Website https://www.neurobopharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.89 USD
  • Last Updated 29-01-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -1.51 -61.51 -64.25 -80.75 -3.65 -4.08 -2.45
    Dividends USD
    Payout Ratio % *
    Shares Mil 4.0 5.0 6.0
    Book Value Per Share * USD 72.78 23.39 19.02 -0.07 0.47
    Free Cash Flow Per Share * USD -26.09 -59.58 -47.6 -19.17
    Return on Assets % -91.95 -538.12 -102.22 -152.68 -122.12 -124.77 -266.52
    Financial Leverage (Average) 1.2 4.83 2.53 1.18 1.49
    Return on Equity % -362.38 -271.97 -403.53 -212.42 -386.97
    Return on Invested Capital % -362.38 -149.68 -210.04 -143.45 -379.37
    Interest Coverage
    Current Ratio 0.38 0.41 6.0 2.97 1.65 6.78 3.03
    Quick Ratio 0.36 0.41 5.83 2.89 1.59 6.68 2.64
    Debt/Equity 2.2 0.010 0.010